104 related articles for article (PubMed ID: 2404444)
1. Octreotide is effective in acromegaly but often results in cholelithiasis.
Daughaday WH
Ann Intern Med; 1990 Feb; 112(3):159-60. PubMed ID: 2404444
[No Abstract] [Full Text] [Related]
2. Therapeutic efficacy of the somatostatin analog SMS 201-995 (octreotide) in acromegaly. Effects of dose and frequency and long-term safety.
Ho KY; Weissberger AJ; Marbach P; Lazarus L
Ann Intern Med; 1990 Feb; 112(3):173-81. PubMed ID: 2404445
[TBL] [Abstract][Full Text] [Related]
3. Long-term treatment of acromegaly with a long-acting analogue of somatostatin, octreotide.
Page MD; Millward ME; Taylor A; Preece M; Hourihan M; Hall R; Scanlon MF
Q J Med; 1990 Feb; 74(274):189-201. PubMed ID: 2111918
[TBL] [Abstract][Full Text] [Related]
4. Cholelithiasis and acromegaly: therapeutic strategies.
Montini M; Gianola D; Pagani MD; Pedroncelli A; Caldara R; Gherardi F; Bonelli M; Lancranjan I; Pagani G
Clin Endocrinol (Oxf); 1994 Mar; 40(3):401-6. PubMed ID: 8187305
[TBL] [Abstract][Full Text] [Related]
5. The role of Sandostatin in acromegaly.
Sassolas G
Metabolism; 1992 Sep; 41(9 Suppl 2):39-43. PubMed ID: 1518432
[TBL] [Abstract][Full Text] [Related]
6. Restoration of gallbladder contractility after withdrawal of long-term octreotide therapy in acromegalic patients.
Shi YF; Zhu XF; Harris AG; Zhang JX; Deng JY
Acta Endocrinol (Copenh); 1993 Sep; 129(3):207-12. PubMed ID: 8212985
[TBL] [Abstract][Full Text] [Related]
7. Short-term continuous infusion of octreotide in acromegaly. Pharmacokinetics and prediction of the response to long-term treatment.
Timsit J; Chanson P; Harris AG; Grass P; Guillausseau PJ; Warnet A; Lubetzki J
Horm Metab Res; 1991 Jan; 23(1):48-9. PubMed ID: 2016081
[No Abstract] [Full Text] [Related]
8. Hepatobiliary and gastrointestinal manifestations of acromegaly.
Ezzat S
Dig Dis; 1992; 10(3):173-80. PubMed ID: 1611713
[TBL] [Abstract][Full Text] [Related]
9. Octreotide long term treatment of acromegaly: effect of drug withdrawal on serum growth hormone/insulin-like growth factor-I concentrations and on serum gastrin/24-hour intragastric pH values.
Plöckinger U; Liehr RM; Quabbe HJ
J Clin Endocrinol Metab; 1993 Jul; 77(1):157-62. PubMed ID: 8325938
[TBL] [Abstract][Full Text] [Related]
10. Growth hormone and insulin-like growth factor-1 in blood and urine as response markers during treatment of acromegaly with octreotide: a double-blind placebo-controlled study.
Fredstorp L; Werner S
J Endocrinol Invest; 1993 Apr; 16(4):253-8. PubMed ID: 8514980
[TBL] [Abstract][Full Text] [Related]
11. Medical management of acromegaly--what and when?
Melmed S
Acta Endocrinol (Copenh); 1993 Jul; 129 Suppl 1():13-7. PubMed ID: 8372605
[TBL] [Abstract][Full Text] [Related]
12. Effective clinical response to long term octreotide treatment, with reduced serum concentrations of growth hormone, insulin-like growth factor-I, and the amino-terminal propeptide of type III procollagen in acromegaly.
Salmela PI; Juustila H; Pyhtinen J; Jokinen K; Alavaikko M; Ruokonen A
J Clin Endocrinol Metab; 1990 Apr; 70(4):1193-201. PubMed ID: 2180976
[TBL] [Abstract][Full Text] [Related]
13. Octreotide stimulates insulin-like growth factor binding protein-1 (IGFBP-1) levels in acromegaly.
Ezzat S; Ren SG; Braunstein GD; Melmed S
J Clin Endocrinol Metab; 1991 Aug; 73(2):441-3. PubMed ID: 1713220
[TBL] [Abstract][Full Text] [Related]
14. A prospective multicenter octreotide dose response study in the treatment of acromegaly.
Ezzat S; Redelmeier DA; Gnehm M; Harris AG
J Endocrinol Invest; 1995 May; 18(5):364-9. PubMed ID: 7594225
[TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of long-term octreotide therapy of acromegaly: results of a multicenter trial in 103 patients--a clinical research center study.
Newman CB; Melmed S; Snyder PJ; Young WF; Boyajy LD; Levy R; Stewart WN; Klibanski A; Molitch ME; Gagel RF
J Clin Endocrinol Metab; 1995 Sep; 80(9):2768-75. PubMed ID: 7673422
[TBL] [Abstract][Full Text] [Related]
16. Long-term treatment of 189 acromegalic patients with the somatostatin analog octreotide. Results of the International Multicenter Acromegaly Study Group.
Vance ML; Harris AG
Arch Intern Med; 1991 Aug; 151(8):1573-8. PubMed ID: 1872661
[TBL] [Abstract][Full Text] [Related]
17. Effect of octreotide, a somatostatin analog, on sleep apnea in patients with acromegaly.
Grunstein RR; Ho KK; Sullivan CE
Ann Intern Med; 1994 Oct; 121(7):478-83. PubMed ID: 8067645
[TBL] [Abstract][Full Text] [Related]
18. Gall stones and treatment with octreotide for acromegaly.
BMJ; 1989 Nov; 299(6708):1162-3. PubMed ID: 2513036
[No Abstract] [Full Text] [Related]
19. Assessment of gall bladder dynamics, cholecystokinin release and the development of gallstones during octreotide therapy for acromegaly.
Ewins DL; Javaid A; Coskeran PB; Shah S; Butler J; Deprez PH; Miell J; Calam J; Barrett JJ; Dawson JM
Q J Med; 1992 Apr; 83(300):295-306. PubMed ID: 1631261
[TBL] [Abstract][Full Text] [Related]
20. Octreotide treatment of acromegaly during pregnancy.
Mikhail N
Mayo Clin Proc; 2002 Mar; 77(3):297-8. PubMed ID: 11888040
[No Abstract] [Full Text] [Related]
[Next] [New Search]
